Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of BG00012 in Pediatric RRMS
NCT02555215Phase 3Completed
- Sponsor
- Biogen
- Start
- Feb 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Started Feb 2016; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02555215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02555215.